Alan V. Boddy

7.8k total citations
188 papers, 5.9k citations indexed

About

Alan V. Boddy is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Alan V. Boddy has authored 188 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Molecular Biology, 71 papers in Oncology and 44 papers in Pathology and Forensic Medicine. Recurrent topics in Alan V. Boddy's work include Chemotherapy-induced organ toxicity mitigation (43 papers), Cancer therapeutics and mechanisms (31 papers) and Acute Lymphoblastic Leukemia research (28 papers). Alan V. Boddy is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (43 papers), Cancer therapeutics and mechanisms (31 papers) and Acute Lymphoblastic Leukemia research (28 papers). Alan V. Boddy collaborates with scholars based in United Kingdom, Australia and United States. Alan V. Boddy's co-authors include S. Murray Yule, Andrew D.J. Pearson, Gareth J. Veal, Michael Cole, Jeffrey R. Idle, Andrew J. McLachlan, L Price, Jeffry Adiwidjaja, David Jamieson and David R. Newell and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Alan V. Boddy

188 papers receiving 5.7k citations

Peers

Countries citing papers authored by Alan V. Boddy

Since Specialization

Citations

This map shows the geographic impact of Alan V. Boddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan V. Boddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan V. Boddy more than expected).

Fields of papers citing papers by Alan V. Boddy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan V. Boddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan V. Boddy. The network helps show where Alan V. Boddy may publish in the future.

Co-authorship network of co-authors of Alan V. Boddy

This figure shows the co-authorship network connecting the top 25 collaborators of Alan V. Boddy. A scholar is included among the top collaborators of Alan V. Boddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan V. Boddy. Alan V. Boddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimization of a clofarabine‐based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia 2019 ·Pediatric Blood & Cancer ·(unknown), (unknown), (unknown), Jurgen Langenhorst, Alan V. Boddy, (unknown), Rosemary Sutton, Nicola C. Venn, Arjen M. Punt, Vanessa Tyrrell, Michelle Haber, Toby N. Trahair, Loretta M. S. Lau, Glenn M. Marshall, Richard B. Lock	4
2	Investigating the heterogeneity of alkylating agents’ efficacy and toxicity between sexes: A systematic review and meta‐analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study) 2017 ·Pediatric Blood & Cancer ·Brice Fresneau, Allan Hackshaw, Douglas S. Hawkins, Michael Paulussen, J R Anderson, Ian Judson, Saskia Litière, Uta Dirksen, I J Lewis, Henk van den Berg, Nathalie Gaspar, Hans Gelderblom, Jeremy Whelan, Alan V. Boddy, K. Wheatley, Jean‐Pierre Pignon, Florent de Vathaire, Marie‐Cécile Le Deley, Gwénaël Le Teuff	7
3	Precision dosing of targeted anticancer drugs—challenges in the real world 2017 ·Translational Cancer Research ·Hannah Yejin Kim, Jennifer Martin, Andrew J. McLachlan, Alan V. Boddy	6
4	Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer 2016 ·European Journal of Cancer ·Nicola Cresti, Joanne Lee, Emma Rourke, Despina Televantou, David Jamieson, Mark Verrill, Alan V. Boddy	13
5	Plasma Retinol Kinetics and β-Carotene Bioefficacy Are Quantified by Model-Based Compartmental Analysis in Healthy Young Adults with Low Vitamin A Stores 2016 ·Journal of Nutrition ·Michael H. Green, Jennifer Lynn Ford, Anthony Oxley, Joanne Balmer Green, Hyunjin Park, Philip Berry, Alan V. Boddy, Georg Lietz	28
6	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System 2015 ·Molecular Cancer Therapeutics ·Karen E. Parrish, Ling Cen, J. C. Murray, David Calligaris, Sani H. Kizilbash, Rajendar K. Mittapalli, Brett L. Carlson, Mark A. Schroeder, Julieann Sludden, Alan V. Boddy, Nathalie Y.R. Agar, Nicola J. Curtin, William F. Elmquist, Jann N. Sarkaria	66
7	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study 2014 ·Clinical Cancer Research ·Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson, Bruce Morland, Martin Elliott, Quentin Campbell‐Hewson, Guy Makin, Sarah Halford, Gary D Acton, Philip Ross, (unknown), Victoria Lock, Ana Isabel Enríquez Rodríguez, John F. Lyons, Alan V. Boddy, (unknown), Murray Yule, Darren Hargrave	39
8	Adaptive Dosing Approaches to the Individualization of 13- Cis -Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma 2012 ·Clinical Cancer Research ·Gareth J. Veal, Julie Errington, Sophie E. Rowbotham, Nicola A. Illingworth, (unknown), Michael Cole, Ann K. Daly, Andrew D.J. Pearson, Alan V. Boddy	38
9	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP‐glucuronosyltransferases 2010 ·British Journal of Pharmacology ·(unknown), Alan V. Boddy, Ann K. Daly, Gareth J. Veal	14
10	Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma 2009 ·Clinical Cancer Research ·(unknown), Agata Rozanska, Huw D. Thomas, Evan A. Mulligan, Yvette Drew, Deborah J. Castelbuono, Zdeněk Hostomský, Elizabeth Ruth Plummer, Alan V. Boddy, Deborah A. Tweddle, Nicola J. Curtin, Steven C. Clifford	61
11	Pharmacokinetics and Pharmacogenetics of 13-cis-Retinoic Acid in the Treatment of Neuroblastoma 2007 ·Therapies ·Gareth J. Veal, Sophie E. Rowbotham, Alan V. Boddy	8
12	Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide 2005 ·Clinical Cancer Research ·E. Ruth Plummer, Mark R. Middleton, R. Wilson, James Evans, Cheryl Jones, Amanda M. Olson, Alan V. Boddy, Nicola J. Curtin, (unknown), Adrian L. Harris, Peter J. Johnston, Newell, L Robson, R. Dewji, A H Calvert	6
13	A study to investigate the pharmacokinetics of carboplatin and etoposide in infants with neuroblastoma 2005 ·Cancer Research ·Gareth J. Veal, Julie Errington, Caroline Ellershaw, Andrew Pearson, Alan V. Boddy	2
14	Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer 2000 ·British Journal of Cancer ·Alan V. Boddy, (unknown), (unknown), (unknown), (unknown), (unknown), Ruth Plummer, Martin Highley, A H Calvert	1
15	A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration 1999 ·British Journal of Cancer ·(unknown), A. Bowman, Ron Rye, (unknown), Alan V. Boddy, Imran Rafi, G. A. Taylor, A. E. Johnston, Neil J. Clendeninn	12
16	Validation of pharmacologically-guided dosing of carboplatin in paediatric patients 1998 ·British Journal of Cancer ·(unknown), Alan V. Boddy, (unknown), CR Pinkerton, Ian Lewis, Marita Stevens, John Imeson, Rachel Hobson, Newell	2
17	High-dose cyclosporin with etoposide - toxicity and pharmacokinetic interaction in children with solid tumours 1998 ·British Journal of Cancer ·Gianni Bisogno, Fiona Cowie, Alan V. Boddy, (unknown), G. Dick, CR Pinkerton	32
18	The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion 1995 ·Cancer Chemotherapy and Pharmacology ·Alan V. Boddy, Michael Cole, Andrew D.J. Pearson, Jeffrey R. Idle	51
19	Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients 1995 ·European Journal of Cancer ·Alan V. Boddy, (unknown), (unknown), Michael Lind, Jeffrey R. Idle	36
20	Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients 1992 ·Cancer Chemotherapy and Pharmacology ·M Tasso, Alan V. Boddy, L Price, Ruth Wyllie, Andrew D.J. Pearson, Jeffrey R. Idle	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact